SAN JOSE, Calif., Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 11,786,489, which broadens protection of Anixa's novel ovarian cancer vaccine technology.
Read more at prnewswire.comAnixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
